The FDA and European Medicines Agency (EMA) approved two vaccines—T-VEC (Imylgic®) to induce DC production in melanoma and Sipuleucel-T (Provenge®) to supply genes expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastatic prostate cancer, respectively [28]. This evidence concerns the gene CSF2 and metastatic prostate carcinoma.